Significance: Camurati-Engelmann Disease (CED) is a rare autosomal dominant disorder characterized by progressive symmetric diaphyseal sclerosis of the long bones and potential cranial hyperostosis. Since the first description in 1922, less than 200 cases have been described in the international literature. Cranial base involvement is quite variable and results from bony overgrowth leading to foraminal stenosis and neurovascular compromise.
Results:
In the last 40 years, twelve patients carrying the diagnosis of CED were evaluated. Of these, eight (66%) were found to have radiographic evidence of skull base thickening with concurrent cranial signs and symptoms of disease. The average onset of cranial base symptoms was 24 years (15-35 year). Sensorineural hearing loss (SNHL) was the most common finding (50%), followed by vertigo (25%), and visual disturbances (17%); less commonly facial nerve weakness (8%) and brainstem compression (8%) occurred. Four patients underwent a total of six decompression surgeries for aggressive disease and one additionally received cochlear implantation for profound bilateral SNHL.
Conclusion: CED should be included in the differential diagnosis for patients with radiographic evidence of skull base thickening and synchronous cranial neuropathies (most commonly cochleovestibulopathy). In mild forms of disease, patients should be followed with serial examination, audiometric testing and radiography. Those with more symptomatic skull base involvement benefit from wide decompression of involved neurovascular structures. The gene linked to the development of CED codes for the beta-1 subunit of transforming growth factor (TGFB1) and was isolated to chromosome 19q in 2000. Mutations of this gene result in increased TGF activity and subsequent stimulation of osteoblastic bone formation and suppression of osteoclastic resorption.
Skull Base Manifestations of Camurati-Engelmann Disease
Presenting symptoms commonly include musculoskeletal complaints of lower limb weakness, muscle pain and gait unsteadiness, while cranial base manifestations occur in less than a fourth of patients. The mandible is sclerotic in approximately 25% of patients and infrequently may be enlarged. Symptomatic cranial base involvement is variable and is caused by bony overgrowth of the skull base leading to foraminal stenosis and diminished cranial vault volume resulting in neurovascular compromise and increased intracranial pressure (ICP) respectively.
INTRODUCTION ABSTRACT CONTACT
A retrospective chart review from 1968-2008 was performed using the electronic medical record and all patients diagnosed with CED were included. Data were collected with respect to age, sex, presenting symptoms, evaluation, imaging, surgical management and treatment outcomes.
Methods
Despite that over 50% of patients with CED will have radiographically confirmed skull base involvement, less than 25% experience cranial nerve dysfunction. Owing to the symmetric but often irregular cranial base involvement, laterality and progression of individual cranial neuropathies are unpredictable. Some patients may note abrupt unilateral hearing loss, facial nerve paralysis, or vision loss, while others may experience gradual or fluctuating unilateral or bilateral symptoms. Hyperostosis is 2-3 times more common in the anterior and middle fossa compared to the posterior fossa. Cranial neuropathies are thought to be the result of both foraminal narrowing and/or increased ICP.
Surgical decompression remains the primary management of progressive symptomatic skull base involvement. Surgery is technically demanding with sclerotic bony changes, reduced space for supratentorial access, and potential obscuration or loss of critical landmarks. Patients should be counseled on the increased risks associated with surgery and additional measures, such as intraoperative image guidance should be considered particularly for cranial nerve decompression. Cranial base manifestations of disease are mainly caused by foraminal stenosis and increased ICP, as such, interventions addressing both conditions are met with the most success. Bony regrowth following decompression remains a concern. In contrast to limb and torso involvement, medical therapy including corticosteroids and bisphosphonates does not appear to benefit cranial base disease progression or symptomatology.
Discussion
In the last 40 years twelve patients carrying the diagnosis of CED were evaluated and treated at our institution. These included 4 males and 8 females with a mean age of symptom onset at 9.4 years (3-30). Of these, eight (66%) were found to have radiographic evidence of skull base thickening with concurrent cranial signs and symptoms of disease (Table 1) .
The average onset of cranial base symptoms was 24 years (15-35 year). Sensorineural hearing loss (SNHL) was the most common finding (50%), followed by vertigo (25%), and visual disturbances (17%); less commonly facial nerve weakness (8%) and brainstem compression (8%) occurred. Four patients underwent a total of six decompression surgeries for aggressive disease and one additionally received cochlear implantation for profound bilateral SNHL.
Results
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CED is a rare disease that results in symptomatic cranial base hyperostosis in less than one fourth of patients. In asymptomatic and mild forms of disease, patients should be followed with serial examination, audiometric testing and imaging.
Unfortunately, there remains no known pharmacologic or surgical strategy for disease reversal. In contrast to lower extremity disease progression, medical therapy has not been successful in treating skull base disease. Surgery with aggressive wide bony decompression is technically challenging but remains the only means to preserve cranial nerve function for patients with advanced disease. Table 1 . Demographic data, findings and surgical treatments in patients diagnosed with CED associated skull base involvement 
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